Related Experiment Video

Updated: Mar 12, 2026

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.1K

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

Nicholas A Manieri1, Eugene Y Chiang1, Jane L Grogan1

  • 1Department of Cancer Immunology, Genentech, South San Francisco, CA, USA.

Trends in Immunology
|October 30, 2016
PubMed

Insights

Cancer immunotherapies show promise, but not all patients respond. This review explores TIGIT, an inhibitory receptor, and its role in limiting anti-tumor immune responses, offering new therapeutic targets.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Cancer immunotherapies harness the immune system to fight tumors.
  • Immune checkpoints like PD-1/PD-L1 and CTLA-4 are targeted for treatment.
  • Durable responses are limited to a subset of patients, indicating other inhibitory mechanisms exist.

Purpose of the Study:

  • To discuss the role of the TIGIT inhibitory receptor in limiting anti-tumor immune responses.
  • To review TIGIT's mechanisms of action within the cancer immunity cycle.

Main Methods:

  • Literature review of TIGIT's function in cancer immunity.
  • Analysis of TIGIT's role in immune suppression.
  • Exploration of TIGIT's impact on the cancer immunity cycle.

Main Results:

  • TIGIT is an inhibitory receptor expressed by lymphocytes.
  • TIGIT actively suppresses anti-tumor immune responses.
  • Understanding TIGIT mechanisms is crucial for improving immunotherapy efficacy.

Conclusions:

  • TIGIT represents a significant barrier to effective anti-tumor immunity.
  • Targeting TIGIT may enhance patient responses to cancer immunotherapy.
  • Further research into TIGIT pathways is warranted to optimize cancer treatments.

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.5K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K